{"prompt": "['emicizumab as well as bypassing agents for the treatment of breakthrough bleeds. Three', 'Four of these patients have fully recovered and the fifth patient died (death due to serious', 'adverse event of rectal haemorrhage unrelated to emicizumab, with the TMA related to emicizumab', \"and aPCC) fourth patient's condition has improved (see Sections 5.1.1.2 and 5.1.1.3).\", '2.', 'OBJECTIVES AND ENDPOINTS', 'This study will evaluate the safety and tolerability of emicizumab in patients with congenital', 'hemophilia A who have persistent inhibitors against FVIII at enrollment. Specific objectives', 'and corresponding endpoints for the study are outlined below (Table 7).', 'Table 7', 'Objectives and Corresponding Enpoints', 'Objectives', 'Corresponding Endpoints', 'Primary Objective:', 'To evaluate the overall safety and', 'Incidence and severity of all adverse events,', 'tolerability of prophylactic', 'including thromboembolic events, microangiopathic', 'administration of emicizumab', 'hemolytic anemia or TMA (e.g. hemolytic uremic', 'syndrome), systemic hypersensitivity, anaphylaxis,', 'and anaphylactoid events', 'Changes in physical examination findings, vital', 'signs, and laboratory parameters', '3.1', 'DESCRIPTION OF THE STUDY', 'This single-arm, multicenter, open label Phase IIIb clinical study will enroll patients aged 12', 'years or older with congenital hemophilia A who have persistent inhibitors against FVIII at', 'enrollment. Approximately 200 patients with inhibitors will be enrolled globally. Patients will', 'receive prophylactic emicizumab at 3 mg/kg/week subcutaneously for 4 weeks, followed by', '1.5 mg/kg/week subcutaneously for the remainder of the 2-year treatment period (Figure 1).', 'The primary objective of this study is to evaluate the overall safety and tolerability of', 'prophylactic administration of emicizumab in patients with congenital hemophilia A who have', 'persistent inhibitors against FVIII at enrollment. In order to achieve this objective, all adverse', 'events, including adverse events of special interest, will be captured on an ongoing basis, as', 'they occur during the study. Physical examinations, vital signs, and laboratory values will be', 'assessed as per the Schedule of Activities (Appendix 1', 'Schedule of Activities', ').', 'The final analysis will be conducted when all patients have completed 2 years of treatment', 'or have withdrawn, whichever occurs sooner. Patients, or their legally authorized', 'representative, will be asked to report bleed information on an electronic patient-reported', 'outcome (ePRO) device where possible, including site of bleed, type of bleed, time of each', 'individual bleed (day, start and stop time), and treatment for bleed. HRQoL will be assessed', 'Emicizumab - F. Hoffmann-La Roche Ltd', '18 / Protocol MO39129, Version 3']['and the EuroQol Five-Dimension-Five Levels Questionnaire (EQ-5D-5L) will be completed', 'prior to the first emicizumab administration (Week 1), at the Month 3, 6, 12, and 18 month', 'assessments, and at study completion as outlined in the Schedule of Activities (Appendix 1', 'Schedule of Activities', '). Additional secondary endpoints include assessing patient preference for the emicizumab', 'regimen compared with the previous regimen using a questionnaire (EmiPref).', 'For the assessment of anti-FVIII antibodies, functional assays for FVIII inhibitors that utilize a', 'clotting readout (classic Bethesda or Nijmegen assay) cannot be used for patients on', 'emicizumab therapy as emicizumab drives clotting even in the presence of FVIII inhibitors,', 'causing a false-negative test result. After the first dose, local measurement of FVIII inhibitors,', 'if indicated, requires use of an enzyme linked immunosorbent assay- (ELISA-) based test or', 'a chromogenic Bethesda assay. At the discretion of the local investigator, any additional', 'urgent request to assess FVIII inhibitors will need to be sent to a central laboratory (see', 'Appendix 2', 'Schedule of Biomarker Samples', 'for additional information).', 'in dipendent DataMonitoring Committee (iDMC) composed of, at minimum,', 'hemostasis/thrombosis experts and a statistician will be in place throughout the duration', 'of', 'the study and will monitor the study data at pre specified intervals and ad hoc as needed', 'throughout the study.', 'The use of aPCC is to be avoided throughout the study. If bypassing agents are needed to', 'treat breakthrough bleeds or additional treatment to prevent or treat bleeding during', 'surgeries, recombinant activated human Factor VII (rFVIla) should be used at the lowest', 'dose expected to achieve hemostasis. If rVIla is not available or not an option for medical', 'reasons, activated prothrombin complex concentrate (aPCC, including Factor eight inhibitor', 'bypassing activity [FEIBA]) may be used. If aPCC is used, 50 units/kg of aPCC should be', 'administered as an initial dose and it is critical that the dose administered does not exceed', 'the recommended dose (see the local prescribing information for the marketed bypassing', 'agent in question).', 'Drugs intended to control breakthrough bleeds (e.g. rFVII, FVIII, aPCC) or bleeds during surgeries', 'should be used at the lowest dose expected to achieve hemostasis. Given that circulating emicizumab', \"may increase the patient's coagulation potential, the doses required to achieve hemostasis may be\", 'lower than doses used prior to starting emicizumab. Investigators shall discuss at the start of the', 'study with patients recommended doses of any additional coagulation factors used, following the', 'guidance below.', 'The use of aPCC for breakthrough bleed treatment for patients on emicizumab should be avoided if', 'possible, and rFVIIa should be the first option used to treat, starting with no more than 90 g/kg as', 'an initial dose. If aPCC needs to be used, no more than 50 IU/kg should be administered as an initial', 'dose and doses of > 100 U/kg/24 hours or more should be avoided, as cases of TMA and thrombotic', 'events were reported when on average a cumulative amount of > 100 U/kg/24 hours aPCC was', 'Emicizumab - F. Hoffmann-La Roche Ltd', '19 / Protocol MO39129, Version 3']\n\n###\n\n", "completion": "END"}